Inactive Instrument

Lannett Company, Inc.

LCI

US5160122009

(LCI) Alert: Johnson Fistel, LLP Announces Investigation of Lannett Company, Inc.; Long Term Investors Encouraged to Contact Firm

May 23, 2019 at 04:10 pm EDT

SAN DIEGO, May 23, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc. (NYSE: LCI) ("Lannett") and certain of its officers.

In 2017 a securities class action lawsuit was filed on behalf of purchasers of the securities of Lannett from July 15, 2014 and October 31, 2017, (the "Class Period"). The complaint alleges that Defendants made false and misleading statements regarding the Company's drug pricing methodologies and internal controls. On May 15, 2019, Judge Wendy Beetlestone denied defendants motion to dismiss.

If you are a long-term shareholder of Lannett continuously holding shares before July 15, 2014, you may have standing to hold Lannett harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are interested in learning more about your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you email, please include your phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[click here to join this action]

View original content:http://www.prnewswire.com/news-releases/lci-alert-johnson-fistel-llp-announces-investigation-of-lannett-company-inc-long-term-investors-encouraged-to-contact-firm-300856288.html

SOURCE Johnson Fistel, LLP

Latest news about Lannett Company, Inc.

Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	23-06-16	CI
Lannett Company, Inc. Emerged from Bankruptcy	23-06-16	CI
First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	23-06-08	CI
First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	23-06-05	CI
Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Motion for Joint Administration Approved for Lannett Company, Inc.	23-05-04	CI
Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	23-05-04	CI
Global markets live: Ford, AMD, Starbucks, Estee Lauder, CVS Health....	23-05-03
Motion for Joint Administration Filed by Lannett Company, Inc.	23-05-03	CI
Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	23-05-02	CI
Lannett Company, Inc. Filed for Bankruptcy	23-05-02	CI
Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	23-04-25	CI
John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	23-04-14	CI
John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	23-04-14	CI
Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	23-04-04	CI
Top Premarket Gainers	23-02-02	MT
Transcript : Lannett Company, Inc., Q2 2023 Earnings Call, Feb 01, 2023	23-02-01
Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M	23-02-01	MT
Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34	23-02-01	MT
Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-01	CI
Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022	23-02-01	CI
Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023	23-02-01	CI
Lannett to Implement 1-for-4 Reverse Stock Split	23-01-26	MT
Lannett Company Provides Development Update on Biosimilar Insulin Products	23-01-04	CI
Jeffrey Farber Announces Not to Stand for the Re-Election to the Board of Lannett Company, Inc	22-11-29	CI

Chart Lannett Company, Inc.

Duration

Period

More charts

Company Profile

Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company's product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
OTSUKA HOLDINGS CO., LTD.	+18.59%	22.25B
SANDOZ GROUP AG	+13.82%	14.39B
CIPLA LIMITED	+12.83%	13.55B
ZYDUS LIFESCIENCES LIMITED	+38.02%	11.27B
ONO PHARMACEUTICAL CO., LTD.	-9.80%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	5.01B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-8.24%	4.51B

Generic Pharmaceuticals